IGC Pharma Adds Ichor Research as New Site for CALMA Phase 2 Alzheimer’s Trial September 29, 2025 Read More »
IGC Pharma Announces Preclinical Data Demonstrating TGR-63’s Dual Action on Alzheimer’s Pathology September 24, 2025 Read More »
IGC Pharma Reports 50% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer’s Agitation Trial September 22, 2025 Read More »
IGC Pharma, Inc. Receives Third Award from the NIA for Excellence in Code Clarity, Reproducibility, and Usability for Alzheimer’s Detection September 9, 2025 Read More »
IGC Pharma Expands CALMA Phase 2 Trial to Island Health’s Royal Jubilee Hospital in Canada September 2, 2025 Read More »
IGC Pharma receives Notice of Allowance for Novel THC Microdose-Based Treatment for Stammering, Stuttering, and Tourette’s Syndrome August 28, 2025 Read More »
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the “Reports Q1 results. We believe more positive clinical data and progress in 2025 to be strong catalysts for stock. Raising P/T to $4.50.” August 27, 2025 Read More »
IGC Pharma Expands CALMA Phase 2 Trial with Site at Lynn Health Science Institute in Oklahoma City August 25, 2025 Read More »
IGC Pharma Reports First Quarter Fiscal 2026 Financial Results; Company Accelerates Phase 2 Alzheimer’s Trial August 19, 2025 Read More »
IGC Pharma Highlights Alzheimer’s Pipeline with Encouraging Preclinical Data on IGC-M3 and Advancing Phase 2 Cannabinoid-Based IGC-AD1 August 12, 2025 Read More »
